Our story: Mycophoral
Roughly a year ago, during an R&D discussion at Biotech International Institute (BII), someone asked: “Why don't we quit treating mushroom science like a story… and begin treating it like a blueprint?” That question inspired Mycophorol™, a patent-pending research candidate created just for preclinical studies. Its purpose is to explore how things work, not to make any medical claims.
The vision.
Mycophorol™ is being studied as a hybrid molecule made from fungi. It’s a single structure that brings together two main ideas from mushroom research independently beforehand, but now with our product, they can be studied together in a new light:
a psilocybin-inspired tryptamine motif (indole-based neuroactive structural elements)
hericenone-related structures associated with Lion’s Mane (Hericium erinaceus)
It’s not a mixture or a supplement; it is something that allows us to study two areas simultaneously. Instead, it’s a single molecular platform connected by a biocompatible linker, allowing us to study it as a single system.
What are we actually studying?
At BII, our R&D mission is to combine biotechnology, chemistry, and engineering to create scalable, sustainable molecules and materials. We aim to move these from discovery through engineering, validation, scale-up, and finally to responsible commercialization.
For Mycophorol™, our early research focuses on understanding how it works:
Receptor interactions (such as serotonin-family receptors, including 5-HT₂A, in vitro)
Neurotrophic pathway readouts (including how we can study tracking of markers like BDNF in controlled assays)
Neuroinflammation models (standard in vitro inflammatory signaling in how environments function)
Cognition-related proxies (choosing what models to refine future hypotheses, without making clinical conclusions)
To be clear, this research is still preclinical. We are not making any claims about safety, effectiveness, or therapeutic potential at this stage.
Why are we showing this now?
We believe real innovation comes from discipline, not hype.
Mycophorol™ is patent-pending and still in preclinical research. Right now, we are working on how to make it, test its stability, and run experiments to understand how it works.
We are also looking for collaborators in chemistry, analytical methods like LC–MS and NMR, and preclinical research methods.
Question for the neuroscience + biotech community:
If you could design a hybrid scaffold to study brain resilience, what would you focus on first:
receptor mapping, trophic signaling, or inflammation modulation?
Share your answer in the comments. If you’re interested in collaborating on research, let’s connect.
Mycophorol™: https://www.biotechinternationalinstitute.com/mycophorol-article
Biotech International Institute: https://www.biotechinternationalinstitute.com/
